Scarica l'app Stockscreener
3.86
0.26%
-0.01
Dopo l'orario di chiusura:
3.86
Precedente Chiudi:
$3.87
Aprire:
$3.85
Volume 24 ore:
36,467
Relative Volume:
0.35
Capitalizzazione di mercato:
$157.00M
Reddito:
-
Utile/perdita netta:
$-78.92M
Rapporto P/E:
-1.8922
EPS:
-2.04
Flusso di cassa netto:
$-72.87M
1 W Prestazione:
+1.05%
1M Prestazione:
+12.21%
6M Prestazione:
+27.39%
1 anno Prestazione:
-43.90%
Intervallo 1D:
$3.80
$4.00
Intervallo di 1 settimana:
$3.70
$4.00
Portata 52W:
$2.47
$7.07
Vigil Neuroscience Inc Stock (VIGL) Company Profile
Nome
Vigil Neuroscience Inc
Settore
Industria
Telefono
857-254-4445
Indirizzo
100 FORGE ROAD, WATERTOWN
Vigil Neuroscience Inc Stock (VIGL) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2023-03-31 | Iniziato | Mizuho | Buy |
| 2022-09-16 | Iniziato | Wedbush | Outperform |
| 2022-08-29 | Iniziato | H.C. Wainwright | Buy |
| 2022-02-01 | Iniziato | Guggenheim | Buy |
| 2022-02-01 | Iniziato | Jefferies | Buy |
| 2022-02-01 | Iniziato | Morgan Stanley | Equal-Weight |
| 2022-02-01 | Iniziato | Stifel | Buy |
Mostra tutto
Vigil Neuroscience Inc Borsa (VIGL) Ultime notizie
Vigil Neuroscience to Present at Guggenheim Healthcare Innovation Conference - GlobeNewswire
abrdn plc Makes New $799,000 Investment in Vigil Neuroscience, Inc. (NASDAQ:VIGL) - MarketBeat
Vigil Neuroscience retains stock target on TREM2 potential - Investing.com
Vigil Neuroscience retains stock target on TREM2 potential By Investing.com - Investing.com Australia
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Vigil Neuroscience, Inc. (NASDAQ: VIGL) - Victoria Advocate
Quanterix Welcomes Ivana Magovčević-Liebisch, Ph.D., J.D. to Board of Directors - BioSpace
Quanterix Appoints Ivana Magovčević-Liebisch to Board of Directors - citybiz
Point72 Asset Management L.P. Buys New Position in Vigil Neuroscience, Inc. (NASDAQ:VIGL) - Defense World
Point72 Asset Management L.P. Acquires New Position in Vigil Neuroscience, Inc. (NASDAQ:VIGL) - MarketBeat
Vigil Neuroscience, Inc. (NASDAQ:VIGL) Shares Purchased by Ensign Peak Advisors Inc - MarketBeat
Vigil Neuroscience, Inc. (NASDAQ:VIGL) Short Interest Down 20.3% in September - MarketBeat
Is Vigil Neuroscience (NASDAQ:VIGL) In A Good Position To Deliver On Growth Plans? - Yahoo Finance
Certified Advisory Corp Grows Stake in Vanguard Dividend Appreciation ETF (NYSEARCA:VIG) - Defense World
Vanguard Dividend Appreciation ETF (NYSEARCA:VIG) Shares Purchased by Harmony Asset Management LLC - Defense World
Evergreen Capital Management LLC Sells 380 Shares of Vanguard Dividend Appreciation ETF (NYSEARCA:VIG) - Defense World
Circle Wealth Management LLC Acquires 383 Shares of Vanguard Dividend Appreciation ETF (NYSEARCA:VIG) - Defense World
Garden State Investment Advisory Services LLC Acquires 743 Shares of Vanguard Dividend Appreciation ETF (NYSEARCA:VIG) - Defense World
VICOR 72 HOUR DEADLINE ALERT: Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors With Losses in Excess of $100,000 of Deadline in Class Action Lawsuit Against Vicor CorporationVICR - Business Wire
INVESTOR DEADLINE MONDAY: Robbins Geller Rudman & Dowd LLP Announces that Vicor Corporation Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit – VICR - ForexTV.com
Vigil Neuroscience shares maintain Outperform rating on positive FDA update - Investing.com
WCG Wealth Advisors LLC Has $3 Million Position in Vanguard Dividend Appreciation ETF (NYSEARCA:VIG) - Defense World
Bradley Foster & Sargent Inc. CT Cuts Position in Vanguard Dividend Appreciation ETF (NYSEARCA:VIG) - Defense World
1,275 Shares in Vanguard Dividend Appreciation ETF (NYSEARCA:VIG) Bought by One Capital Management LLC - Defense World
Vanguard Dividend Appreciation ETF (NYSEARCA:VIG) Shares Sold by ProVise Management Group LLC - Defense World
Vigil Neuroscience shares maintain Outperform rating on positive FDA update By Investing.com - Investing.com Australia
FDA lifts partial clinical hold on Vigil Neuroscience’s Phase I VG-3927 trial - Clinical Trials Arena
FDA lifts hold on Vigil Neuroscience's Alzheimer trial By Investing.com - Investing.com Canada
Vigil Neuroscience Announces FDA Has Removed Partial Clinical Hold on VG-3927 - ForexTV.com
Vigil stock gains as FDA removes partial hold (NASDAQ:VIGL) - Seeking Alpha
FDA lifts hold on Vigil Neuroscience's Alzheimer trial - Investing.com India
Vigil Neuroscience Advances Alzheimer’s Trial, Eyes 2025 Data - TipRanks
Vigil Neuroscience Says FDA Lifts Partial Hold Alzheimer's-Treatment Trial - MarketWatch
Vigil Neuroscience rises as FDA lifts partial hold on Alzheimer’s disease trial - XM
The Neuroscience Market Research Explores 2024: Advancing Brain Research and Therapeutics - WhaTech
Vigil Neuroscience to Present at Cantor Global Healthcare Conference - GlobeNewswire
Vigil Neuroscience, Inc. (NASDAQ:VIGL) Short Interest Update - MarketBeat
Vigil Neuroscience, Inc. (NASDAQ:VIGL) Short Interest Down 23.7% in August - Defense World
Vigil Neuroscience (NASDAQ:VIGL) Trading 5% Higher - MarketBeat
Neurodegenerative Disorder Therapeutics Market Insights Discussed Regarding Size And Outlook 2024-2033 - WhaTech
A stock that deserves closer examination: Vigil Neuroscience Inc (VIGL) - US Post News
You might want to take a look at Vigil Neuroscience Inc (VIGL) now - SETE News
Vigil Neuroscience to Present at Upcoming September Investor Conferences - GlobeNewswire
Vanguard Group Inc. Acquires 95,276 Shares of Vigil Neuroscience, Inc. (NASDAQ:VIGL) - Defense World
Q3 2024 EPS Estimates for Vigil Neuroscience, Inc. Decreased by Analyst (NASDAQ:VIGL) - MarketBeat
Research Analysts Offer Predictions for Vigil Neuroscience, Inc.’s Q3 2024 Earnings (NASDAQ:VIGL) - Defense World
Vigil Neuroscience (NASDAQ:VIGL) Stock Rating Reaffirmed by HC Wainwright - Defense World
Vigil Neuroscience, Inc. (NASDAQ:VIGL) Short Interest Down 20.4% in July - MarketBeat
Vigil Neuroscience stays 'on-track'; Stifel reaffirms buy rating on stock - Investing.com India
Vigil Neuroscience stays 'on-track'; Stifel reaffirms buy rating on stock By Investing.com - Investing.com Canada
Vigil Neuroscience (NASDAQ:VIGL) Price Target Cut to $16.00 by Analysts at Guggenheim - Defense World
HC Wainwright Analysts Cut Earnings Estimates for Vigil Neuroscience, Inc. (NASDAQ:VIGL) - MarketBeat
Vigil Neuroscience Inc Azioni (VIGL) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Vigil Neuroscience Inc Azioni (VIGL) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Magovcevic-Liebisch Ivana | President and CEO |
Nov 20 '23 |
Buy |
3.75 |
4,000 |
15,000 |
207,687 |
2.02%
0.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Capitalizzazione:
|
Volume (24 ore):